| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-01-13 |
| タイトル |
|
|
タイトル |
Acute amivantamab-induced myocardial injury in a patient with epidermal growth factor receptor-mutant lung cancer: a first case report |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
epidermal growth factor receptor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
mesenchymal-epithelial transition |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
lung cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
amivantamab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
myocardial injury |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
case report |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Kaneko, Seiya
Dotsu, Yosuke
Inoue, Tomoaki
Motokawa, Tetsufumi
Yoshimuta, Tsuyoshi
Mori, Mayako
Morikawa, Toru
Honda, Noritaka
Akagi, Kazumasa
Tomono, Hiromi
Matsuo, Midori
Taniguchi, Hirokazu
Takemoto, Shinnosuke
Mukae, Hiroshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Amivantamab, a bispecific antibody against epidermal growth factor receptor and mesenchymal-epithelial transition receptors, has been approved for certain types of non-small cell lung cancer; however, it is known to cause severe adverse events. The management of such adverse events is necessary for maintaining the therapeutic efficacy of amivantamab. The frequency of cardiotoxicity caused by amivantamab is low, despite its association with a high incidence of severe adverse events. Most of the adverse events are cardiovascular events caused by thrombosis. No reports of amivantamab-induced myocardial injury have been published. Case presentation: We present the first case of drug-induced myocardial injury, detected with tachycardia but not associated with any cardiovascular events, immediately after initiating amivantamab. Echocardiography revealed a decrease in left ventricular ejection fraction and global longitudinal strain, while contrast-enhanced cardiac magnetic resonance imaging showed shortened T1 values, leading to a diagnosis of amivantamab-induced myocardial injury. Furthermore, with early detection and therapeutic interventions, we were able to continue treatment with amivantamab without interruption. Conclusions: When treating patients with amivantamab, oncologists should screen for cardiac disease-related symptoms, even in the absence of elevated cardiac serum biomarkers. Furthermore, when amivantamab-induced myocardial injury is suspected, a cardiologist should be consulted promptly, as the dysfunction may be reversible. |
|
言語 |
en |
| 書誌情報 |
en : Frontiers in Oncology
巻 15,
p. art. no. 1708575,
発行日 2025-12-09
|
| 出版者 |
|
|
出版者 |
Frontiers Media SA |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2234-943X |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.3389/fonc.2025.1708575 |
| 権利 |
|
|
権利情報 |
© 2025 Kaneko, Dotsu, Inoue, Motokawa, Yoshimuta, Mori, Morikawa, Honda, Akagi, Tomono, Matsuo, Taniguchi, Takemoto and Mukae. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Frontiers in Oncology, 15, art. no. 1708575; 2025 |
|
言語 |
en |
FO15_1708575.pdf (6.9 MB)
